A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas

Phase 2 Completed 57 enrolled Dana-Farber Cancer Institute Merck Sharp & Dohme LLC · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This research study is studying a combination of drugs (chemotherapy + Immunotherapy) as a possible treatment for liposarcoma, leiomyosarcoma, or undifferentiated pleomorphic sarcoma that has spread and has not responded to standard treatment.

Timeline

Start: 2019-06-04
Primary completion: 2024-07-16
Completion: 2024-07-16

Publications

Haddox CL, Nathenson MJ, Mazzola E, Lin JR, Baginska J, Nau A, Weirather JL, Choy E, Marino-Enriquez A, Morgan JA, Cote GM, Merriam P, Wagner AJ, Sorger PK, Santagata S, George S. Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates. Clin Cancer Res. 2024 Apr 1;30(7):1281-1292. doi: 10.1158/1078-0432.CCR-23-2250.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Eribulin	Small molecule	1.4 mg/m2	Intravenous
Subject	Pembrolizumab	Monoclonal antibody	200 mg	Intravenous

A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas

Summary

Timeline

Publications

Drugs

Indications